LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

LLY

1,136.41

-0.5%↓

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

AZN

178.86

-2.36%↓

Strona główna・Stock List・Johnson and Johnson
Search

Johnson and Johnson

Closed

SectorHealthcare

238.85 0.91

Buy

Price update 10 cze 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

236.66

Max

240.83

Key metrics

By Trading Economics

Income

119M

5.2B

Sales

-502M

24B

P/E

Sector Avg

25.899

49.888

EPS

2.7

Dividend yield

2.31

Profit margin

21.756

Employees

138,200

EBITDA

182M

6.4B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+12.41% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.31%

2.38%

Next Earnings

15 lip 2026

Next Dividend date

8 wrz 2026

Market Stats

By TradingEconomics

Market Cap

-35B

538B

Previous open

237.94

Previous close

238.85

News Sentiment

By Acuity

25%

75%

51 / 344 Ranking in Healthcare

Johnson and Johnson Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

8 cze 2026, 12:48 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Firefly Bio for $1 Billion

DJ

Read

24 kwi 2026, 13:27 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Atraverse Medical to Bolster Cardiac Device Portfolio

DJ

Read

8 cze 2026, 12:04 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Firefly Acquisition Adds Proprietary Degrader Antibody Conjugate Platform >JNJ

DJ

Read

8 cze 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire Firefly Bio for $1 Billion in Cash >JNJ

DJ

Read

8 cze 2026, 12:00 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Acquire Firefly Bio, Inc. To Expand Oncology Pipeline With Novel Degrader Antibody Conjugate Platform >JNJ

DJ

Read

23 kwi 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

DJ

Read

22 kwi 2026, 11:27 UTC

Earnings

Intuitive Surgical Earnings Show Big Beats Don't Always Spark Stock Rallies -- Barrons.com

DJ

Read

14 kwi 2026, 19:38 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Read

14 kwi 2026, 14:13 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Read

14 kwi 2026, 12:57 UTC

Earnings

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

DJ

Read

14 kwi 2026, 11:19 UTC

Earnings

Johnson & Johnson Beats Earnings Estimates. Cancer Treatments Help Drive the Quarter. -- Barrons.com

DJ

Read

14 kwi 2026, 10:34 UTC

Earnings

Johnson & Johnson Stock Rises on Earnings Beat. These Segments Boosted the Quarter. -- Barrons.com

DJ

Read

14 kwi 2026, 10:20 UTC

Market Talk
Earnings

J&J Sees Path to Double-Digit Growth by End of Decade -- Market Talk

DJ

Read

14 kwi 2026, 10:20 UTC

Market Talk
Earnings

J&J's Tremfya Sales Continue to Surge -- Market Talk

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Anticipate Additional Rounds of VBP in China Throughout Year, Heavier in Second Half of Year >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Expect Heavier Investment in First Half of 2026 Year >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With Innovative Medicine, Expect More Pronounced Sales Impact From Newly Launched Products as 2026 Progresses>JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Announce Planned Enterprise Business Review for Dec. 8, 2026 >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Anticipate Higher EPS Growth in Second Half of Year Vs First Half >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Expect Continued Acceleration of Newly Launched Products as Year Progresses With Normalized Seasonality >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With MedTech, Surgery Transformation Sales Headwinds Expected to Increase Through Year >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Adjusted Operational EPS $11.30-$11.50 Vs Prior View $11.28-$11.48 >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: Anticipate Fairly Consistent Operational Sales Growth in First and Second Half With 53rd Week Affecting Second Half >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: With Innovative Medicine, Anticipate Generic Competition for Opsumit (Second Half in U.S.) and Simponi (First Half in EU; Potentially Second Half in U. S.) >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Adj. Operational Sales Growth in Range of 5.6%-6.6% Vs Prior View 5.4%-6.4% >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: 1Q Innovative Medicine Operational Sales Growth Driven Primarily by Darzalex, Carvykti, Erleada, Rybrevant/Lazcluze, Tremfya and Spravato >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Raises 2026 View To Sales $100.3B-$101.3B Vs Prior View $100B-$101B >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson 1Q Orthopaedics Sales $2.38B >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson: 1Q MedTech Business Growth Driven Primarily by Electrophysiology Products, Abiomed, Shockwave as Well as Trauma >JNJ

DJ

Read

14 kwi 2026, 10:20 UTC

Earnings

Johnson & Johnson Sees 2026 Operational Sales of $99.7B-$100.7B Vs Prior View $99.5B-$100.5B>JNJ

DJ

Read

Peer Comparison

Price change

Johnson and Johnson Forecast

Price Target

By TipRanks

12.41% upside

12 Months Forecast

Average 266.4 USD  12.41%

High 285 USD

Low 250 USD

Based on 17 Wall Street analysts offering 12 month price targets forJohnson and Johnson - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

17 ratings

12

Buy

5

Hold

0

Sell

Based on 17 analysts giving stock ratings to Johnson and Johnson - Dist in the past 3 months.

Sentiment

By Acuity

51 / 344 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Other stocks from the sector

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%

AZN

AstraZeneca PLC

178.86

↓-2.36%
help-icon Live chat